Frances Lee, MD, on stigma's role in ALD care and why women may progress to advanced disease faster than men.
News|Articles|May 1, 2025
Hepatology Month in Review: April 2025
Author(s)Abigail Brooks, MA
Fact checked by: Victoria Johnson
The month in review spotlights hepatic FDA and pipeline news as well as new research on alcohol and obesity's impact on liver health and PBC.
Advertisement
Advertisement
April brought a mix of progress and persistent challenges to the field of
Related to this article
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
Stress led all triggers, and a sense of an impending attack was the most reliable prodrome in patients with HAE-C1INH in the US HAEA Scientific Registry.
Stay updated with the latest healthcare breakthroughs, including the FDA approval of insulin efsitora alfa-gobe (Onswik).
Approval is based on 36-week data from BRAVE-AA-PEDS, in which 42% of patients on the 4 mg dose achieved a SALT score of 20 or less, compared with 5% on placebo.
The FDA approved once-daily oral zilurgisertib for FOP in patients aged 12 years and older after the phase 2 PROGRESS trial showed reduced new heterotopic ossification vs placebo.
Approval covers patients aged ≥2 years with frequently relapsing or steroid dependent disease in complete remission.
As the FDA weighs its first psychedelic approval, Sarah Norman, MPP, says training, credentialing, and reimbursement are lagging while patients are already asking.
Advertisement
Advertisement